Evidencias científicas sobre la hepatitis B y la infección por SARS-CoV-2: revisión integradora
DOI:
https://doi.org/10.17058/reci.v13i4.18618Palabras clave:
Hepatitis B; SARS-CoV-2; COVID-19.Resumen
Justificación y Objetivo: la hepatitis B es una enfermedad infecciosa contagiosa causada por un virus de la familia hepadnaviridae, de distribución mundial, y representa un grave problema de salud mundial. Su patología puede haberse visto afectada por la pandemia de COVID-19, provocada por el virus SARS-CoV-2, y son posibles desenlaces graves cuando se superponen tipos virales. Este estudio buscó describir los niveles de evidencia científica de las investigaciones realizadas sobre el tema, estableciendo una relación entre la infección por el virus de la hepatitis B y la infección por el SARS-CoV-2. Contenido: revisión integradora de la literatura, con búsquedas realizadas en las bases de datos Medical Literature Analysis and Retrieval System Online y Scientific Electronic Library Online, con un análisis centrado en la descripción del diseño metodológico y en la clasificación del nivel de evidencia. Conclusión: la producción científica sobre la hepatitis B asociada a la infección por SARS-CoV-2 corresponde, en su mayoría, a investigaciones con bajo nivel de evidencia. Las publicaciones seleccionadas presentaron limitaciones como la ocurrencia de estudios con un número reducido de muestras, la falta de datos subsidiarios de los pacientes en tratamiento y la ocurrencia de selección no aleatoria. Los resultados sugieren la necesidad de seguir investigando para mejorar la tecnología, identificar los factores de riesgo, intervenir terapéuticamente y realizar investigación clínica avanzada, con el fin de promover prácticas sanitarias basadas en la evidencia.
Descargas
Citas
Silva AL da, Vitorino RR, Esperidião-Antonio V, et al. Hepatites virais: B, C e D: atualização. Rev Soc Bras Clín Méd [Internet]. junho de 2012 [citado 22 de abril de 2023];10(3). Disponível em: http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&src=google&base=LILACS&lang=p&nextAction=lnk&exprSearch=621489&indexSearch=ID.
World Health Organization. Hepatitis B [Internet]. Geneva: WHO; 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Coordenação Coordenação Geral de desenvolvimento da Epidemiologia em Serviços. Guia de Vigilância em Saúde. 3.ed. Brasília: Ministério da Saúde; 2019.
Dias JA, Cerutti Júnior C, Falqueto A. Fatores associados à infecção pelo vírus da hepatite B: um estudo caso-controle no município de São Mateus, Espírito Santo. Epidemiol E Serviços Saúde. dezembro de 2014;23(4):683–90. http://dx.doi.org/10.5123/S1679-49742014000400010
Farias NS de O, Holcman MM, Compri AP, et al. Ocorrência de hepatite B em gestantes e seguimento de crianças expostas no estado de São Paulo, em 2012*. Epidemiol E Serviços Saúde. maio de 2020. http://dx.doi.org/10.5123/s1679-49742020000200018
Brito SBP, Braga IO, Moraes MM, et al. Immunopathological mechanisms involved in SARS-CoV-2 infection. J Bras Patol E Med Lab, 2020. https://doi.org/10.5935/1676-2444.20200056
Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. junho de 2020;20(6):363–74. https://doi.org/10.1038/s41577-020-0311-8
World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. Geneva: WHO; 2023. Available from: https://covid19.who.int/
Mendes KDS, Silveira RC de CP, Galvão CM. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto Contexto - Enferm. dezembro de 2008;17(4):758–64. https://doi.org/10.1590/S0104-07072008000400018
Souza MT de, Silva MD da, Carvalho R de. Revisão Integrativa: O que é e como fazer. Einstein São Paulo. março de 2010;8(1):102–6. https://doi.org/10.1590/S1679-45082010RW1134
Oliveira MS de, Valle S da CN do, Souza RM de, et al. Evidências científicas sobre a hepatite Delta no Brasil: revisão integrativa da literatura. Acta Paul Enferm. dezembro de 2017;30(6):658–66. https://doi.org/10.1590/1982-0194201700091
Melnyk BM, Fineout-Overholt E. Evidence-based practice in nursing & healthcare. A guide to best practice. Philadelphia: Lippincot Williams & Wilkins; 2005. Making the case for evidence based practice. p.239-344.
Jiménez-Mendoza J, Rivera-López F, González-Lara M, et al. Seroprevalence of hepatitis B and C viruses in moderate and severe COVID-19 inpatients: A cross-sectional study at a referral center in Mexico. Ann Hepatol. maio de 2022;27(3):100684. https://doi.org/10.1016/j.aohep.2022.100684
Choe JW, Jung YK, Yim HJ, et al. Clinical Effect of Hepatitis B Virus on COVID-19 Infected Patients: A Nationwide Population-Based Study Using the Health Insurance Review & Assessment Service Database. J Korean Med Sci. 2022;37(4): e29. https://doi.org/10.3346/jkms.2022.37.e29
Librero Jiménez M, López Garrido MÁ, Fernández Cano MC. Letter to the editor: Reactivation of HBV triggered by SARS‐CoV‐2 in a patient with cirrhosis. Hepatology. março de 2022;75(3):765–6. https://doi.org/10.1002/hep.32271
Sagnelli C, Pisaturo M, Curatolo C, et al. Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic. World J Gastroenterol. 14 de novembro de 2021;27(42):7271–84. https://doi.org/10.3748/wjg.v27.i42.7271
Gómez Camarero J, Badia Aranda E, Quiñones Castro R, et al. Cribado de infección por virus de la hepatitis B y C en pacientes hospitalizados con infección por SARS-CoV-2. Gastroenterol Hepatol. abril de 2022;45(4):256–64. https://doi.org/10.1016/j.gastrohep.2021.09.002
Kazmi SK, Khan FMA, Natoli V, et al. Viral hepatitis amidst COVID‐19 in Africa: Implications and recommendations. J Med Virol. janeiro de 2022;94(1):7–10. https://doi.org/10.1002/jmv.27330
Jindal A. Letter to the Editor: Outcomes in chronic hepatitis B infection and COVID‐19 Not always benign! Hepatology. janeiro de 2022;75(1):230–230. https://doi.org/10.1002/hep.32108
Lv X, Yang J, Deng K. Letter to the Editor: Unanswered questions about hepatitis B virus infection in patients with COVID‐19. Hepatology. janeiro de 2022;75(1):229–229. https://doi.org/10.1002/hep.32098
Alqahtani SA, Buti M. COVID-19 and Hepatitis B Infection. Antivir Ther. novembro de 2020;25(8):389–97. https://doi.org/10.3851/IMP3382
Pley CM, McNaughton AL, Matthews PC, Lourenço J. The global impact of the COVID-19 pandemic on the prevention, diagnosis and treatment of hepatitis B virus (HBV) infection. BMJ Glob Health. janeiro de 2021;6(1): e004275. https://doi.org/10.1136/bmjgh-2020-004275
Liu R, Zhao L, Cheng X, Han H, et al. Clinical characteristics of COVID‐19 patients with hepatitis B virus infection — a retrospective study. Liver Int. abril de 2021;41(4):720–30. https://doi.org/10.1111/liv.14774
Ding Z yang, Li G xun, Chen L, et al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol. junho de 2021;74(6):1295–302. https://doi.org/10.1016/j.jhep.2020.12.012
Yu R, Tan S, Dan Y, et al. Effect of SARS-CoV-2 coinfection was not apparent on the dynamics of chronic hepatitis B infection. Virology. Janeiro de 2021;553:131–4. https://doi.org/10.1016/j.virol.2020.11.012
Ali E, Ziglam H, Kohla S, et al. A Case of Fulminant Liver Failure in a 24-Year-Old Man with Coinfection with Hepatitis B Virus and SARS-CoV-2. Am J Case Rep. 3 de setembro de 2020. https://doi.org/10.12659/AJCR.925932
Rodríguez‐Tajes S, Miralpeix A, Costa J, López‐Suñé E, et al. Low risk of hepatitis B reactivation in patients with severe COVID‐19 who receive immunosuppressive therapy. J Viral Hepat. janeiro de 2021;28(1):89–94. https://doi.org/10.1111/jvh.13410
Wu J, Yu J, Shi X, et al. Epidemiological and clinical characteristics of 70 cases of coronavirus disease and concomitant hepatitis B virus infection: A multicentre descriptive study. J Viral Hepat. Janeiro de 2021;28(1):80–8. https://doi.org/10.1111/jvh.13404
Lv XH, Yang JL, Deng K. Clinical Outcomes of COVID-19 Patients With Chronic Hepatitis B Virus Infection Still Need To Be Explored. Clin Gastroenterol Hepatol. dezembro de 2020;18(13):3055–6. https://doi.org/10.1016/j.cgh.2020.07.068
Zhang B, Huang W, Zhang S. Clinical Features and Outcomes of Coronavirus Disease 2019 (COVID-19) Patients With Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. outubro de 2020;18(11):2633–7. https://doi.org/10.1016/j.cgh.2020.06.011
Anugwom CM, Aby ES, Debes JD. Inverse Association Between Chronic Hepatitis B Infection and Coronavirus Disease 2019 (COVID-19): Immune Exhaustion or Coincidence? Clin Infect Dis. 5 de junho de 2020; ciaa592. https://doi.org/10.1093/cid/ciaa592
Lv XH, Yang JL, Deng K. COVID-19 Patients With Hepatitis B Virus Infection. Am J Gastroenterol. junho de 2021;116(6):1357–8. https://doi.org/10.1002/hep.32098
El Dib RP. Como praticar a medicina baseada em evidências. J Vasc Bras. março de 2007;6(1):1–4. https://doi.org/10.1590/S1677-54492007000100001
Brandau R, Monteiro R, Braile DM. Importância do uso correto dos descritores nos artigos científicos. Rev Bras Cir Cardiovasc. março de 2005;20(1):VII–IX. https://doi.org/10.1590/S0102-76382005000100004
##submission.downloads##
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Marcelo Siqueira de Oliveira, Elissandra Pinheiro Costa, José André Pinho da Silva
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
The author must state that the paper is original (has not been published previously), not infringing any copyright or other ownership right involving third parties. Once the paper is submitted, the Journal reserves the right to make normative changes, such as spelling and grammar, in order to maintain the language standard, but respecting the author’s style. The published papers become ownership of RECI, considering that all the opinions expressed by the authors are their responsibility. Because we are an open access journal, we allow free use of articles in educational and scientific applications provided the source is cited under the Creative Commons CC-BY license.
